All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CAIX chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CAIX. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CAIX antibody linked to CD28 transmembrane domain/ endodomain and OX40, CD3-zeta signaling domains. And the vector product was designed for the treatment of renal cell carcinoma (RCC).
CAR Construction : G250 scFv-41BB-CD28ζ Fig.1 Fluorescence-activated cell sorting analysis. CAR-positive rate of lentivirus-transduced NK92 cells. NK92 cells were transduced with empty lentivirus vector (Ctrl-NK92) or lentivirus containing the CAIX-specific CAR encoding sequence (CAR-NK92) and were selected with puromycin. Zhang, Q., Xu, J., Ding, J., Liu, H., Li, H., Li, H., Lu, M., Miao, Y., Wang, Z., Fu, Q., & Zheng, J. (2018). Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma. Oncology reports, 40(6), 3714–3724. |
CAR Construction : G250 scFv-41BB-CD28ζ Fig.2 Western blot analysis. Western blot analysis of the CAR expression in NK92 cells with a monoclonal anti-human CD3ζ antibody. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was also detected as an internal control. Zhang, Q., Xu, J., Ding, J., Liu, H., Li, H., Li, H., Lu, M., Miao, Y., Wang, Z., Fu, Q., & Zheng, J. (2018). Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma. Oncology reports, 40(6), 3714–3724. |
CAR Construction : G250 scFv-41BB-CD28ζ Fig.3 Functional studies. Specific cytokine release of CAIX-specific CAR-NK92 cells against CAIX+ cells. Zhang, Q., Xu, J., Ding, J., Liu, H., Li, H., Li, H., Lu, M., Miao, Y., Wang, Z., Fu, Q., & Zheng, J. (2018). Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma. Oncology reports, 40(6), 3714–3724. |
CAR Construction : G250 scFv-41BB-CD28ζ Fig.4 Cytotoxicity assay. Specific cytotoxicity exhibited by CAIX-specific CAR-NK92 cells against CAIX+ target cells. Zhang, Q., Xu, J., Ding, J., Liu, H., Li, H., Li, H., Lu, M., Miao, Y., Wang, Z., Fu, Q., & Zheng, J. (2018). Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma. Oncology reports, 40(6), 3714–3724. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CAIX scFv h(CD28-OX40-CD3ζ) CART, pCDCAR1 (CAR-T-3-M305-2XZ). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION